From the slides it seems they are taking both forward for now. You are going to need a (large) CV outcomes trial at some point so it seems like they will have to eventually pick one. All things equal why not go with the once daily even though it is a bit further behind. It would be nice to have a slide comparing efficacy w current agents.
Market Data 
Markets 
AI
